Presenting at Psych Congress 2022, researchers assessed the safety and efficacy of COMP360 psilocybin therapy in adults with treatment-resistant depression.
Psych Congress 2022 News
Researchers sought to determine if lumateperone therapy improves quality of life and functional impairment in patients with bipolar disorder.
Researchers assessed clinician interactions with a prescription digital therapeutic dashboard, and the effect of this interaction on patient engagement and clinical outcomes.
Researchers evaluated changes in ADHD severity in children following treatment with SDX/d-MPH in a laboratory classroom setting.
Researchers conducted a survey that targeted clinicians’ perspectives on managing schizophrenia with oral antipsychotics vs long-acting injectable antipsychotic agents.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Study authors assessed whether xanomeline-trospium could demonstrate a significant and meaningful improvement in Positive and Negative Syndrome Scale (PANSS) scores in patients with schizophrenia.
Researchers evaluated the effect of caffeine consumption with viloxazine extended-release in adults with attention-deficit/hyperactivity disorder.
Researchers analyzed the effects of using anticholinergics to treat tardive dyskinesia (TD) and developed recommendations for TD differentiation, appropriate use of anticholinergics, and more.
Researchers assessed the utility of implementing depression screening with the Patient Health Questionnaire in inpatient psychiatric care.
Researchers identified additional solriamfetol-activated targets and compared them with wake-promoting agents and traditional stimulants.
Researchers retrospectively analyzed pharmacogenetic data in patients with major depressive disorder to improve medication selection and/or dosing.
Researchers investigated during behavior in children with ADHD who received treatment with serdexmethylphenidate/dexmethylphenidate.
Researchers sought to better understand the role of psychiatrists in treating patients with mild cognitive impairment or mild Alzheimer disease and dementia.
Researchers assessed real-world data to determine the clinical outcomes in patients with schizophrenia who have cognitive dysfunction.
A study was conducted to determine if a novel ketamine infusion protocol can address the current efficacy-effectiveness gap in treatment of depression.